Themis Medicare Board Approves Financial Results, Equity Warrants, and Key Appointments
Themis Medicare Limited's Board approved Q3 FY26 financial results. The company also approved the issuance of convertible equity warrants to promoters and appointed Mr. Nagraj Mogaveera as Interim Company Secretary. Mr. Pradeep M. Chandan resigned from his position.
The approval of financial results is routine. However, the proposed issuance of convertible equity warrants to promoters and the appointment of new key management personnel are significant corporate actions that could impact the company's structure and future funding.
The announcement includes routine financial results, management changes, and a proposal for equity issuance, which are standard corporate actions. While the financial results themselves might have positive or negative aspects, the overall announcement is informational.
Themis Medicare Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report from M/s. Krishaan & Co.
In personnel changes, the Board noted the resignation of Mr. Pradeep M. Chandan as Company Secretary, Compliance Officer & Key Managerial Personnel (KMP) effective February 13, 2026. Concurrently, Mr. Nagraj Mogaveera was appointed as the Interim Company Secretary, Compliance Officer & KMP, effective February 14, 2026. Mr. Mogaveera is a qualified Company Secretary with 8 years of experience.
The Board also approved a proposal for the issuance of convertible equity warrants to Promoter/Promoter Groups via preferential allotment. This issuance is subject to necessary regulatory and shareholder approvals. A Preferential Issue Committee has been constituted to finalize the terms and conditions.
Additionally, the Board approved the inter-se transfer of up to 3% of the paid-up equity share capital of Gujarat Themis Biosyn Limited (GTBL) held by Themis Medicare Limited to another Promoter/Promoter Group, to be executed at the prevailing market price. This internal transfer will not alter the overall Promoter and Promoter Group shareholding or control.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.